AXWAY
20.4.2016 08:01:53 CEST | Business Wire | Press release
Axway , a market leader in digital business enablement, is pleased to be the technology partner of Les Echos, the leading business and financial daily media in France, in support of its premier Hackathon event, “Hackapress des Echos ” in Paris, France. In less than 48 hours, 50 developers and designers in eight teams will compete to deliver the most innovative code that will better enable Les Echos’ use of data to enrich editorial work. With a successful track record enabling hackathons and other digital transformation initiatives, Axway will provide the digital platform for the event.
Today’s digital economy forces organizations to reinvent traditional business with innovative services. Many of them take advantage of hackathons to find new creative ways to provide better customer experiences and to build a digital culture between teams.
With the objective to reenergize the way Les Echos journalists work with their content in today’s digital age, “Hackapress des Echos” will help to forge connections between student developers, designers, and startups. Axway commits to innovation by supporting partners’ hackathon initiatives with API Management , providing technological means for hackathoners to utilize data intelligently to engage with their digital ecosystem, harvest information from data sources, and develop new methods for their projects.
“We are looking forward to seeing what creative and original projects the teams are able to develop, and this is exciting,” said Jeanine Banks, executive vice president, global products and solutions. “We believe that the future of digital business relies not only on APIs and other digital transformation technologies, but also the young minds of those who innovate.”
To stimulate and assist participants in preparing their projects, representatives from Les Echos (including journalists) will be present as mentors, observers, or participants. Teams will then present their projects at the conclusion of the event. The jury will be composed of Francis Morel, Chairman of Groupe Les Echos; Henri Gibier, Director of Editorials Developments Groupe Les Echos; Digital Village (start-ups and individuals freelancers specialize in digital); and Raise investment company.
The prize for winners, sponsored by Axway, will be presented by Francis Morel, and Bruno Patino (Director of the Journalism School of Sciences Po).
WHAT: Hackapress des Echos
WHEN: April 28-29, 2016
WHERE: Sciences Po Paris, 27 Rue Saint-Guillaume, 75007 Paris
PARTNERS OF HACKATHON DES ECHOS: Axway, Sciences Po, Digital Village, Digital Campus, Paris City Hall and Raise Endowment Fund
WHO: Students, freelancers, startups and observing outsiders
REGISTRATION: All attendees must register, here .
Follow Axway’s news on Twitter: @Axway #APIFirst #DigitalBusiness
About Axway
Axway (Euronext:AXW.PA) empowers more than 11,000 customers worldwide to collaborate smarter, innovate faster and engage better with their partners, developers and customers. From integration technology that securely connects people, processes and things to an engagement platform that enables API management, identity management, mobile app development and analytics, Axway solutions are enabling digital business. Axway is registered in France with headquarters in the United States. More information is available at: www.axway.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20160419006912/en/
Contact:
Media
Neil Desai, 415-856-5150
Blanc & Otus
neil.desai@blancandotus.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom